In addition, we examined the expression of c‐Met and β‐catenin by immunohistochemical (IHC) staining in EGFR‐TKIs resistant NSCLC patients, and consistent with the results observed in the database, elevated levels of β‐catenin expression were detected in c‐Met overexpressing patients (Figure S2, Supporting Information). The gene discussed is MET; the disease is non-small cell lung carcinoma.